PRINCETON, N.J. — Sandoz has launched a rivastigmine patch, a treatment for dementia, in the U.S. market.
The Novartis subsidiary said Wednesday that its rivastigmine transdermal system is an authorized generic version of the Exelon patch, marketed by Novartis Pharmaceuticals Corp. Sandoz is marketing its rivastigmine patch in 13.3-mg strength, the same strength as the branded product.
Rivastigmine patch is indicated for the treatment of mild, moderate and severe memory problems (dementia) related to Alzheimer’s disease. The medication also is used to treat people with mild to moderate memory problems associated with Parkinson’s disease.
“Sandoz is pleased to make rivastigmine patch available as a generic option for patients with memory problems associated with Alzheimer’s disease,” stated Peter Goldschmidt, president of Sandoz. “Rivastigmine has been studied for more than a decade in clinical trials and is the only Alzheimer’s disease treatment that comes in the form of a patch, with the medication absorbed through the skin.”
U.S. sales for the rivastigmine patch totaled about $646 million for the 12 months ended in June 2015, according to IMS Health data reported by Sandoz.